A recently published review found that approximately 1 in every 200 patients undergoing hip replacement will develop a venous thromboembolism before hospital discharge when current venous thromboembolism preventive medications are used.
The findings were recently published in the Journal of the American Medical Association and also revealed that 1 in every 100 patients undergoing knee replacement will develop a venous thromboembolism (VTE).
“These estimates are of value to individuals and organizations seeking to evaluate institutional VTE event rates against contemporary benchmarks,” Jean-Marie Januel, RN, MPH, and colleagues wrote in their review. “Our above-mentioned rate estimates provide these contemporary benchmarks.”
The findings were recently published in the Journal of the American Medical Association and also revealed that 1 in every 100 patients undergoing knee replacement will develop a venous thromboembolism (VTE).
“These estimates are of value to individuals and organizations seeking to evaluate institutional VTE event rates against contemporary benchmarks,” Jean-Marie Januel, RN, MPH, and colleagues wrote in their review. “Our above-mentioned rate estimates provide these contemporary benchmarks.”
